ERTEK, SIBEL
ERTEK, SIBEL
Mostra
records
Risultati 1 - 3 di 3 (tempo di esecuzione: 0.009 secondi).
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
2014 Cicero AF; Tartagni E; Ertek S.
Nutraceuticals for metabolic syndrome management: from laboratory to benchside.
2014 Cicero AF; Tartagni E; Ertek S.
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
2014 Cicero AF; Tartagni E; Ertek S.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. | Cicero AF; Tartagni E; Ertek S. | 2014-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
| Nutraceuticals for metabolic syndrome management: from laboratory to benchside. | Cicero AF; Tartagni E; Ertek S. | 2014-01-01 | CURRENT VASCULAR PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data | Cicero AF; Tartagni E; Ertek S. | 2014-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |